Last week, the Patent Trial and Appeal Board (PTAB) instituted 3 inter partes review proceedings concerning patents on Alexion’s brand-name eculizumab, Soliris, a complement inhibitor that treats rare diseases. Amgen is the petitioner in all 3 cases, which were filed in February of this year.
Last week, the Patent Trial and Appeal Board (PTAB) instituted 3 inter partes review (IPR) proceedings concerning patents on Alexion’s brand-name eculizumab, Soliris, a complement inhibitor that treats rare diseases. Amgen is the petitioner in all 3 cases, which were filed in February of this year.
IPR proceedings are trials conducted by the PTAB that allow the board to review the patentability of 1 or more claims of a patent, and IPRs are instituted if there is a reasonable likelihood that the petitioner will prevail on at least 1 claim challenged. Decisions in instituted IPRs are typically issued within 1 year.
The first case, IPR2019-00739, is related to US Patent Number 9,725,504, which concerns a method of treatment related to paroxysmal nocturnal hemoglobinuria by complement inhibition. The second case, IPR2019-00740, concerns US Patent Number 9,718,880, which relates to formulation. Finally, case IPR2019-00741, is related to US Patent Number 9,732,149, which concerns composition of matter.
News of the IPR institutions comes just months after Amgen announced that its proposed eculizumab biosimilar, ABP 959, showed pharmacokinetic and pharmacodynamic equivalence to Soliris in a phase 1 study. The biosimilar also demonstrated similar safety and immunogenicity to its reference in the study.
Alexion has been attempting to “convert” patients currently receiving Soliris to its follow-up C5 complement inhibitor, Ultomiris, as Alexion’s chief executive officer Ludwig Hanston said earlier this year. Ultomiris offers less frequent administration than Soliris, but to date, Ultomiris carries 1 FDA-approved indication (PNH) to Soliris’ 4 (PNH, atypical hemolytic uremic syndrome, myasthenia gravis, and neuromyelitis optica spectrum disorder).
Alexion has also been highly reliant on Soliris for its revenue; last quarter, the drug brought in $980.8 million for the company, versus just $54.2 million for Ultomiris.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.